Callan Family Office LLC Takes Position in Harmony Biosciences Holdings, Inc. $HRMY

Callan Family Office LLC acquired a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the second quarter, HoldingsChannel reports. The institutional investor acquired 16,054 shares of the company’s stock, valued at approximately $585,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HRMY. EverSource Wealth Advisors LLC raised its stake in Harmony Biosciences by 589.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after purchasing an additional 643 shares during the last quarter. Allworth Financial LP lifted its holdings in Harmony Biosciences by 286.7% in the 4th quarter. Allworth Financial LP now owns 812 shares of the company’s stock valued at $30,000 after purchasing an additional 602 shares in the last quarter. Leonteq Securities AG acquired a new stake in shares of Harmony Biosciences during the 4th quarter worth about $30,000. National Bank of Canada FI acquired a new stake in shares of Harmony Biosciences during the 3rd quarter worth about $40,000. Finally, Clearstead Advisors LLC grew its holdings in shares of Harmony Biosciences by 145.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock worth $44,000 after buying an additional 699 shares in the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

HRMY opened at $38.95 on Wednesday. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $40.87. The company’s 50 day simple moving average is $36.51 and its 200 day simple moving average is $32.74. The stock has a market capitalization of $2.27 billion, a PE ratio of 12.65, a P/E/G ratio of 0.36 and a beta of 0.96. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.45 and a current ratio of 3.48.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.28 EPS for the quarter, topping the consensus estimate of $0.96 by $0.32. The firm had revenue of $261.28 million during the quarter, compared to analyst estimates of $250.77 million. Harmony Biosciences had a net margin of 18.88% and a return on equity of 20.06%. Harmony Biosciences’s revenue for the quarter was up 30.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.92 earnings per share. As a group, sell-side analysts expect that Harmony Biosciences Holdings, Inc. will post 3.77 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Zacks Research lowered shares of Harmony Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Harmony Biosciences in a research report on Thursday, July 16th. Oppenheimer reaffirmed an “outperform” rating and issued a $70.00 target price on shares of Harmony Biosciences in a research note on Tuesday, August 4th. UBS Group reiterated a “neutral” rating and issued a $37.00 price target on shares of Harmony Biosciences in a report on Wednesday, August 5th. Finally, Wall Street Zen raised Harmony Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday, August 16th. Four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $45.50.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.